Celldex Therapeutics (CLDX)

Company Profile

Celldex is a clinical stage biotechnology company dedicated to developing monoclonal and bispecific antibodies that address devastating diseases for which available treatments are inadequate. Our pipeline includes antibody-based therapeutics which have the ability to engage the human immune system and/or directly effect critical pathways to improve the lives of patients with inflammatory diseases and many forms of cancer.

Company profile

Ticker

CLDX

Exchange

NASDAQ

Website

www.celldex.com

CEO

Anthony Marucci

Incorporated

Delaware

Location

New Jersey

Fiscal year end

Dec 31

Sector

Manufacturing > Biological Product (except Diagnostic) Manufacturing

Industry (SIC)

In Vitro & In Vivo Diagnostic Substances

Ortho Clinical Diagnostics • QuidelOrtho • Idexx Laboratories • Myriad Genetics • Neogen • Lantheus • Meridian Bioscience • Lucira Health • Heska Corp. • Intellia Therapeutics ...

Former names

AVANT IMMUNOTHERAPEUTICS INC, T CELL SCIENCES INC

SEC CIK

0000744218

Corporate docs

Articles of Incorporation & Bylaws

Underwriting Agreements

Plans of Reorganization

Indentures

Material Contracts & Credit Agreements

Subsidiaries Lists

Subsidiaries

Celldex Therapeutics Switzerland GmbH ...

IRS number

133191702

CLDX stock data

1M 1Y 5Y

Analyst ratings and price targets

Last 3 months

Latest filings (excl ownership)

View all

4 May 23

Celldex Reports First Quarter 2023 Financial Results and Provides Corporate Update

4 May 23

ARS

2022 FY

Annual report to shareholders

25 Apr 23

28 Feb 23

Celldex Reports Fourth Quarter and Year End 2022 Financial Results and Provides Corporate Update

28 Feb 23

8-K

Celldex Therapeutics Announces Appointment of Rita Jain, M.D. to Board of Directors

9 Nov 22

Celldex Reports Third Quarter 2022 Financial Results and Provides Corporate Update

9 Nov 22

Transcripts

View all

CLDX

Earnings call transcript

2021 Q4

1 Mar 22

CLDX

Earnings call transcript

2020 Q2

6 Aug 20

CLDX

Earnings call transcript

2019 Q2

8 Aug 19

CLDX

Earnings call transcript

2018 Q4

7 Mar 19

CLDX

Earnings call transcript

2018 Q2

8 Aug 18

CLDX

Earnings call transcript

2017 Q3

7 Mar 18

Latest ownership filings

View all

SC 13G/A

WELLINGTON MANAGEMENT GROUP LLP

VIKING GLOBAL INVESTORS LP

WELLINGTON MANAGEMENT GROUP LLP

Financial summary

Financial statements Chart CLDX financial data

Quarter (USD)	Mar 23	Dec 22	Sep 22	Jun 22
Revenue
Cost of revenue
Operating income
Operating margin
Net income
Net profit margin
Cash on hand
Change in cash
Diluted EPS

Annual (USD)	Dec 22	Dec 21	Dec 20	Dec 19
Revenue
Cost of revenue
Operating income
Operating margin
Net income
Net profit margin
Cash on hand
Change in cash
Diluted EPS

Cash burn rate (est.)	Burn method: Change in cash		Burn method: Operating income		Burn method: FCF (opex + capex)
	Last Q	Avg 4Q	Last Q	Avg 4Q	Last Q	Avg 4Q
Cash on hand (at last report)	54.12 mm	54.12 mm	54.12 mm	54.12 mm	54.12 mm	54.12 mm
Cash burn (monthly)	(no burn)	(no burn)	10.82 mm	10.37 mm	9.52 mm	8.98 mm
Cash used (since last report)	n/a	n/a	23.59 mm	22.60 mm	20.76 mm	19.57 mm
Cash remaining	n/a	n/a	30.53 mm	31.52 mm	33.37 mm	34.55 mm
Runway (months of cash)	n/a	n/a	2.8	3.0	3.5	3.8

Beta Read what these cash burn values mean

Financial data from company earnings reports.

Institutional ownership, Q4 2022

CLDX institutional ownership history Ownership history

13F holders	Current	Prev Q	Change
Total holders	166	155	+7.1%
Opened positions	30	24	+25.0%
Closed positions	19	30	-36.7%
Increased positions	50	58	-13.8%
Reduced positions	56	37	+51.4%

13F shares	Current	Prev Q	Change
Total value	2.14 tn	1.37 bn	+156495.2%
Total shares	48.66 mm	45.88 mm	+6.1%
Total puts	225.20 k	210.50 k	+7.0%
Total calls	531.60 k	503.60 k	+5.6%
Total put/call ratio	0.4	0.4	+1.3%

Largest owners	Shares	Value	Change
FMR	7.06 mm	$314.89 bn	+0.7%
Wellington Management	4.65 mm	$207.16 bn	+50.9%
BLK Blackrock	3.22 mm	$143.73 bn	+3.0%
RTW Investments	3.08 mm	$137.46 bn	0.0%
Vanguard	2.51 mm	$112.03 bn	+1.5%
STT State Street	2.29 mm	$102.13 bn	NEW
Ra Capital Management	2.08 mm	$92.48 bn	0.0%
Redmile	1.98 mm	$88.13 bn	-0.4%
BLVGF Bellevue	1.80 mm	$80.23 bn	0.0%
Kynam Capital Management	1.61 mm	$71.55 bn	+0.3%

Largest transactions	Shares	Bought/sold	Change
STT State Street	2.29 mm	+2.29 mm	NEW
Wellington Management	4.65 mm	+1.57 mm	+50.9%
Citadel Advisors	760.25 k	-740.84 k	-49.4%
Point72 Asset Management	505.80 k	+370.80 k	+274.7%
Eventide Asset Managment	1.46 mm	-328.75 k	-18.3%
Jennison Associates	1.56 mm	+281.30 k	+22.1%
TSP Capital Management	269.90 k	+269.90 k	NEW
GS Goldman Sachs	449.58 k	-214.85 k	-32.3%
GMT Capital	0.00	-204.54 k	EXIT
Vivo Capital	0.00	-198.98 k	EXIT

Data from 13F filings, for the last complete 13F reporting period. For most recent data, click the ownership history button. Values as filed, not updated for current price. Long positions only.

Recent insider trades

CLDX insider ownership history Insider history

Date	Owner	Security	Transaction	Code	Indirect	10b5-1	$Price	#Shares	$Value	#Remaining
16 Feb 23	Jain Rita	NQSO Common Stock	Grant	Acquire A	No	No	42.34	17,100	724.01 k	17,100
7 Dec 22	Keler Tibor	Common Stock, par value $0.001 per share	Sell	Dispose S	No	No	36.9283	16,860	622.61 k	7,357
7 Dec 22	Keler Tibor	Common Stock, par value $0.001 per share	Option exercise	Acquire M	No	No	2.78	16,860	46.87 k	24,217
7 Dec 22	Keler Tibor	Incentive Stock Option Common Stock	Option exercise	Dispose M	No	No	2.78	16,860	46.87 k	43,140
18 Aug 22	Cavanaugh Sarah	Common Stock	Sell	Dispose S	No	No	36.3757	1,355	49.29 k	1,284
18 Aug 22	Cavanaugh Sarah	Common Stock	Option exercise	Acquire M	No	No	9.0165	1,355	12.22 k	2,639
18 Aug 22	Cavanaugh Sarah	Incentive Stock Option Common Stock	Option exercise	Dispose M	No	No	9.0165	1,355	12.22 k	10,103
17 Aug 22	Young Diane C.	Common Stock	Option exercise	Acquire M	No	No	2.71	45,000	121.95 k	47,115
17 Aug 22	Young Diane C.	Common Stock	Sell	Dispose S	No	No	37.3008	19,000	708.72 k	2,115
17 Aug 22	Young Diane C.	Common Stock	Option exercise	Acquire M	No	No	10.38	19,000	197.22 k	21,115